Prevnar 13 Loses ‘Routine’ Endorsement For Older Adults In CDC Panel Vote
ACIP still supports use of Pfizer’s pneumococcal vaccine in immunocompetent individuals ages 65 years and older based on shared clinical decision-making, but concludes that routine immunization is no longer warranted due to herd effect from pediatric vaccination.
You may also be interested in...
Advisory Committee on Immunization Practices’ October vote on use of Pfizer’s Prevnar 20 and Merck & Co’s Vaxneuvance was more restrictive than intended, inadvertently leaving out guidance for people who were previously vaccinated with Prevnar 13.
Pfizer's Prevnar 20 and Merck's Vaxneuvance are launching simultaneously and are expected to help drive vaccines growth for both big pharmas.
Advisory Committee on Immunization Practices recommends vaccination based on shared clinical decision-making in individuals ages 27-45 years old – but says only those at high risk of contracting HPV are likely to benefit and should get the vaccine.